The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP)

Dupilumab and other biologics have revolutionized the management of recalcitrant polyps in patients with chronic rhinosinusitis with nasal polyposis (CRSwNP). Despite strong evidence for the efficacy of dupilumab in treating polyps, factors such as cost and uncertain efficacy over surgery have limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardison, Scott A., Senior, Brent A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537999/
https://www.ncbi.nlm.nih.gov/pubmed/37759322
http://dx.doi.org/10.1186/s40463-023-00668-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10537999/
https://www.ncbi.nlm.nih.gov/pubmed/37759322
http://dx.doi.org/10.1186/s40463-023-00668-z

Ejemplares similares